Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Total Liabilities
Everything the company owes to creditors and other parties.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 7.0% from a year ago
Total liabilities stood at $8.64M at the end of Q1 FY2026, up 7.0% from a year earlier and up 3.9% from the prior quarter.
Context
- Total liabilities amounted to 4.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +7.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.32M USD
- Year-over-year change
- +7.4%
- 1-year CAGR
- +7.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.32M | +7.4% |
| FY2024 | 2024-12-31 | 7.75M | — |
Total Liabilities vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's Mar 2026 total liabilities of $8.64M is the 7th highest of the 10 companies compared; the peer median is $9.76M.
- Its year-over-year change of +7.0% is the 8th highest of 10, against a peer median of +34.3%.
- Total liabilities amounts to 4.2% of total assets for OACC, versus a peer median of 5.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | Mar 2026 | $21.4M | +50.0% | — | 6.9% |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | Mar 2026 | $15.77M | +24.0% | — | 6.8% |
| Mar 2026 | $14.53M | +1852.6% | — | 5.1% | |
| Mar 2026 | $13.99M | +4450.2% | — | 5.3% | |
| Mar 2026 | $9.76M | +2161.9% | — | 3.9% | |
| Mar 2026 | $9.52M | +17.1% | -7.8% | 5.1% | |
OACCOaktree Acquisition Corp. III Life Sciences | Mar 2026 | $8.64M | +7.0% | — | 4.2% |
| Mar 2026 | $8.12M | -1.8% | — | 3.4% | |
| Mar 2026 | $1.34M | -83.6% | -48.0% | 0.6% | |
COPLCopley Acquisition Corp | Mar 2026 | $721.22K | +34.3% | — | 3.1% |
| Peer median (excluding OACC) | $9.76M | +34.3% | -27.9% | 5.1% | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 1.36M | 1.43M |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 0 |
| Total Current Assets | 1.56M | 1.55M |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 193.58M | 201.56M |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 113.28K | 0 |
| Total Non-current Assets | 193.69M | 201.56M |
| Total Assets | 195.25M | 203.11M |
| Account Payables | 0 | 0 |
| Short-term Debt | 11.82K | 11.82K |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 179.98K | 1.29M |
| Total Current Liabilities | 727.32K | 1.3M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 7.02M | 7.02M |
| Total Non-current Liabilities | 7.02M | 7.02M |
| Total Liabilities | 7.75M | 8.32M |
| Common Stock | 193.58M | 201.56M |
| Retained Earnings | (6.08M) | (6.77M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | 187.5M | 194.79M |
| Total Debt | 11.82K | 11.82K |
| Net Debt | (1.35M) | (1.42M) |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.